| 1 |
Wagner VF, Northrup H. Mucopolysaccharidosis Type III. }$} "$GeneReviews^{(R)}$") [Internet]. Seattle: University of Washington; 2019 (updated on 2019 Sep 19). https://www.ncbi.nlm.nih.gov/books/NBK546574/
|
| 2 |
Bellettato CM, Scarpa M, Bellettato CM. Possible strategies to cross the blood-brain barrier. Ital J Pediatr 2018;44(S2):S131.
|
| 3 |
Zelei T, Csetneki K, Voko Z, Siffel C, Zelei T. Epidemiology of Sanfilippo syndrome: results of a systematic literature review. Orphanet J Rare Dis 2018;13:53.
DOI
|
| 4 |
Andrade F, Aldamiz-Echevarria L, Llarena M, Couce ML. Sanfilippo syndrome: Overall review. Pediatr Int 2015;57:331-8.
DOI
|
| 5 |
Kim JH, Chi YH, Kim GH, Yoo HW, Lee JH. Long-term clinical course of a patient with mucopolysaccharidosis type IIIB. Korean J Pediatr 2016;59(S1):S37-S40.
DOI
|
| 6 |
Sanchez-Covarrubias L, Slosky LM, Thompson BJ, Davis TP, Ronaldson PT. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des 2014;20:1422-49.
DOI
|
| 7 |
Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2:3-14.
DOI
|
| 8 |
King B, Setford ML, Hassiotis S, Trim PJ, Duplock S, Tucker JN, et al. Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder. Exp Neurol 2016;278:11-21.
DOI
|
| 9 |
Wijburg FA, Whitley CB, Muenzer J, Gasperini S, Del Toro M, Muschol N, et al. Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: A phase IIb randomized trial. Mol Genet Metab 2019;126:121-130.
DOI
|
| 10 |
Lu C-T, Zhao Y-Z, Wong HL, Cai J, Peng L, Tian X-Q. Current approaches to enhance CNS delivery of drugs across the brain barriers. Intl J Nanomed 2014;9:2241-57.
|
| 11 |
Mikitsh JL, Chacko AM. Pathways for small molecule delivery to the central nervous system across the blood-brain barrier. Perspect Medicin Chem 2014;6:11-24.
DOI
|
| 12 |
Muhlstein A, Gelperina S, Kreuter J. Development of nanoparticle-bound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis VI. Pharmazie 2013;68:549-54.
|
| 13 |
Gustavsson S, Ohlin Sjostrom E, Tjernberg A, Janson J, Westermark U, Andersson T, et al. Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice. Mol Genet Metab Rep 2019;21:100510.
DOI
|
| 14 |
de Ruijter J, Valstar MJ, Narajczyk M, Wegrzyn G, Kulik W, Ijlst L, et al. Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol. 2012;71:110-20.
DOI
|
| 15 |
Hersh DS, Wadajkar AS, Roberts N, Perez JG, Connolly NP, Frenkel V, et al. Evolving drug delivery strategies to overcome the blood brain barrier. Curr Pharm Des 2016;22:1177-93.
DOI
|
| 16 |
Grabrucker A, Chhabra R, et al. Nanoparticles as blood-brain barrier permeable CNS targeted drug delivery systems. In: Fricker G, et al, ed. The blood brain barrier. Topics in medicinal chemistry. Berlin: Springer Heidelberg; 2014. p.71-89.
|
| 17 |
Mayer FQ, Adorne MD, Bender EA, de Carvalho TG, Dilda AC, Beck RC, et al. Laronidase-functionalized multiple-wall lipid-core nanocapsules: promising formulation for a more effective treatment of mucopolysaccharidosis type I. Pharm Res 2015;32:941-54.
DOI
|
| 18 |
Salvalaio M, Rigon L, Belletti D, D'Avanzo F, Pederzoli F, Ruozi B, et al. Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders. PLoS One 2016;11:0156452.
|
| 19 |
Tomanin R, Zanetti A, Zaccariotto E, D'Avanzo F, Bellettato CM, Scarpa M. Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases. Acta Paediatr 2012;101:692-701.
DOI
|
| 20 |
Wolf DA, Banerjee S, Hackett PB, Whitley CB, McIvor RS, Low WC. Gene therapy for neurologic manifestations of mucopolysaccharidoses. Exp Opin Drug Deliv 2015;12:283-96.
DOI
|
| 21 |
Kamata Y, Tanabe A, Kanaji A, Kosuga M, Fukuhara Y, Li XK, et al. Long-term normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharidosis VII. Gene Ther 2003;10:406-14.
DOI
|
| 22 |
Wegrzyn G, Jakobkiewicz-Banecka J, Gabig-Ciminska M, Piotrowska E, Narajczyk M, Kloska A, et al. Genistein: a natural isoflavone with a potential for treatment of genetic diseases. Biochem Soc Trans 2010;38:695-701.
DOI
|
| 23 |
Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N. Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther 2016;27:478-96.
DOI
|
| 24 |
Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target 1998;5:415-41.
DOI
|
| 25 |
Belur LR, Temme A, Podetz-Pedersen KM, Riedl M, Vulchanova L, Robinson N, et al. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I. Hum Gene Ther 2017;28:576-87.
DOI
|
| 26 |
de Ruijter J, Valstar MJ, Narajczyk M, Wegrzyn G, Kulik W, Ijlst L, et al. Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neuro 2012;71:110-20.
DOI
|
| 27 |
Malinowska M, Wilkinson FL, Langford-Smith KJ, Langford-Smith A, Brown JR, Crawford BE, et al. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 2010;5:14192.
|
| 28 |
Piotrowska E, Jakobkiewicz-Banecka J, Maryniak A, Tylki-Szymanska A, Puk E, Liberek A, et al. Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med Sci Monit 2011;17:CR196-202.
DOI
|
webmaster
